Health and Healthcare
Drug Company Buyout Follows Failed Drug Trial (SPPI, ALTH)
Published:
Spectrum Phamaceuticals Inc. (NASDAQ: SPPI) has agreed to acquire rival drug firm Allos Therapeutics Inc. (NASDAQ: ALTH) for $1.82 in cash and one Contingent Value Right (CVR), in a deal worth about $206 million, or $108 million net of Allos’s cash. The CVR will pay Allos shareholders an additional $0.11/share if certain conditions are met.
Allos markets a lymphoma treatment, Folotyn, that complements Spectrum’s Zevalin by treating a different form of the disease. Folotyn generated $50 million US sales last year, and the drug is currently being reviewed for approval in Europe.
Spectrum will finance the acquisition from cash on hand and its revolving credit facility. The company said it does not need to issue new shares to finance the deal, which is expected to close in the second quarter.
Spectrum also announced this morning that its experimental bladder cancer drug failed to meet late stage trial targets. The company said that it would request a meeting with the US FDA to “discuss further steps.”
Spectrum’s shares are down about -9.8% in the pre-market this morning at $11.01 in a 52-week range of 6.94-$16.00. Shares of Allos are up more than 27% at $1.82 in a 52-week range of $1.25-$3.28.
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.